Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 10.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,680,347 shares of the company's stock after acquiring an additional 154,038 shares during the quarter. Victory Capital Management Inc. owned 3.59% of Omnicell worth $58,745,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of OMCL. Principal Financial Group Inc. increased its position in Omnicell by 2.6% in the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock worth $8,553,000 after buying an additional 6,288 shares in the last quarter. Jane Street Group LLC increased its position in Omnicell by 7.4% in the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock worth $2,417,000 after buying an additional 3,725 shares in the last quarter. Invesco Ltd. increased its position in Omnicell by 2.4% in the fourth quarter. Invesco Ltd. now owns 219,453 shares of the company's stock worth $9,770,000 after buying an additional 5,063 shares in the last quarter. Mariner LLC increased its position in Omnicell by 16.1% in the fourth quarter. Mariner LLC now owns 9,075 shares of the company's stock worth $404,000 after buying an additional 1,261 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Omnicell by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after buying an additional 28,573 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Bank of America raised their price objective on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Piper Sandler restated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Finally, Wells Fargo & Company raised their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $45.33.

Omnicell Stock Performance

OMCL traded up $0.23 on Tuesday, reaching $28.26. 476,275 shares of the stock were exchanged, compared to its average volume of 564,720. The company's 50-day moving average price is $29.10 and its 200 day moving average price is $34.04. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. The firm has a market capitalization of $1.32 billion, a PE ratio of 61.44, a PEG ratio of 8.18 and a beta of 0.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same period last year, the company earned $0.03 earnings per share. Omnicell's quarterly revenue was up 9.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.